Usefulness of Pericardial Sclerotherapy for Malignant Pericardial Effusion Associated with Primary Lung Cancer

DOI Web Site 11 References
  • Kaburaki Kyohei
    Department of Respiratory Medicine, Toho University Omori Medical Center
  • Isobe Kazutoshi
    Department of Respiratory Medicine, Toho University Omori Medical Center
  • Sakaguchi Shinji
    Department of Respiratory Medicine, Toho University Omori Medical Center
  • Sano Go
    Department of Respiratory Medicine, Toho University Omori Medical Center
  • Takai Yujiro
    Department of Respiratory Medicine, Toho University Omori Medical Center
  • Homma Sakae
    Department of Respiratory Medicine, Toho University Omori Medical Center

Bibliographic Information

Other Title
  • 原発性肺癌に合併した癌性心膜炎における心膜癒着療法の有用性

Search this article

Description

Purpose. The purpose of this study was to clarify the utility of pericardial sclerotherapy in malignant pericardial effusion associated with primary lung cancer. Subjects and Methods. Of the 908 consecutive patients with primary lung cancer who had been treated from April 1998 through October 2008, malignant pericardial effusion associated with lung cancer was diagnosed in 27 patients. The clinical characteristics and outcome of these 27 patients were analyzed retrospectively. Results. There were 20 men and 7 women with a mean age of 61.3 (38-80 years). Histological subtypes were small cell lung cancer (SCLC) in 6 patients, adenocarcinoma in 16, squamous cell carcinoma in 4, and non-small cell lung cancer (NSCLC) with undetermined histology in 1. The clinical stage was III in 13 and IV in 14, respectively. For the treatment of malignant pericardial effusion associated with lung cancer, pericardiocentesis (without sclerotherapy) was performed in 19 patients, and pericardiocentesis and sclerotherapy were performed in 8 patients. The complications of pericardiocentesis were found in 5 (19%), of whom 1 died. Re-retention of malignant pericardial effusion was found in 4 (21%) in the non-sclerotherapy group. There was a significant improvement in survival time between the sclerotherapy (n=8) and non-sclerotherapy groups (n=19) (p=0.04). There was also a significant improvement in survival time between the sclerotherapy (n=4) and the non-sclerotherapy groups (n=7) with cardiac tamponade (p=0.015). Conclusion. The present study suggested that sclerotherapy for malignant pericardial effusion associated with lung cancer was useful. Sclerotherapy is suggested to be indicated in patients with malignant pericardial effusion.<br>

Journal

  • Haigan

    Haigan 49 (7), 994-998, 2009

    The Japan Lung Cancer Society

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top